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Abstract
Background: Neutrophil elastase level/activity is elevated in a variety of diseases such as atherosclerosis, systolic
hypertension and obstructive pulmonary disease. It is unknown whether obese individuals with prehypertension
also have elevated neutrophil elastase, and if so, whether it has a deleterious effect on pulmonary function.
Objectives: To determine neutrophil elastase levels in obese prehypertensive women and investigate correlations
with pulmonary function tests.
Methods: Thirty obese prehypertensive women were compared with 30 obese normotensive subjects and 30
healthy controls. The study groups were matched for age. Measurements: The following were determined: body
mass index, waist circumference, blood pressure, lipid profile, high sensitivity C-reactive protein, serum neutrophil
elastase, and pulmonary function tests including forced expiratory volume in one second (FEV1), forced vital
capacity (FVC) and FEV1/FVC ratio.
Results: Serum neutrophil elastase concentration was significantly higher in both prehypertensive (405.8 ±
111.6 ng/ml) and normotensive (336.5 ± 81.5 ng/ml) obese women than in control non-obese women (243.9 ±
23.9 ng/ml); the level was significantly higher in the prehypertensive than the normotensive obese women. FEV1,
FVC and FEV1/FVC ratio in both prehypertensive and normotensive obese women were significantly lower than in
normal controls, but there was no statistically significant difference between the prehypertensive and normotensive
obese women. In prehypertensive obese women, there were significant positive correlations between neutrophil
elastase and body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, total
cholesterol, triglyceride, low density lipoprotein cholesterol, high sensitivity C-reactive protein and negative
correlations with high density lipoprotein cholesterol, FEV1, FVC and FEV1/FVC.
Conclusion: Neutrophil elastase concentration is elevated in obese prehypertensive women along with an increase
in high sensitivity C-reactive protein which may account for dyslipidemia and airflow dysfunction in the present
study population.
Background
The seventh report of the Joint National Committee
(JNC-7) proposed a new classification distinguishing
between individuals with normal blood pressure and
established hypertension. The report categorized people
with systolic blood pressure between 120 and 139 mm
Hg or diastolic blood pressure between 80 and 89 mm
Hg as having ‘prehypertension’ [1]. Data from the 1999
and 2000 National Health and Nutrition Examination
Survey (NHANES III) suggested that the prevalence of
prehypertension among adults in the United States was
approximately 31% [2]. Prehypertension is a risk factor
for overt hypertension [3] and future cardiovascular dis-
ease events [4]. Prospective observational studies suggest
the risk of cardiovascular death begins at 115/75 mm * Correspondence: eman.eladawy@yahoo.com
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linear fashion [5].
Leukoprotease activity was first described early in the
20
th century but human neutrophil elastase (NE) was
only identified relatively recently [6]. Intracellular NE is
a key effector molecule of the innate immune system,
with potent antimicrobial activity against Gram negative
bacteria [7], spirochetes [8] and fungi [9]. Its best-
known extracellular manifestation is connective tissue
digestion. NE is capable of digesting virtually every type
of matrix protein, including elastin [10]. Because of its
unique elastic recoil properties, elastin is vital for con-
ferring elasticity on arteries, lungs, ligaments and skin
[11]. Biologically, NE is considered a secretagouge for
cytokines [12] and a modulator of inflammation [13].
Alpha-1 antitrypsin is the major specific inhibitor for
NE [14]. Alpha-1 antitrypsin is an acute phase protein
derived from liver and its concentration rises during
inflammation; it inhibits NE to prevent tissue injury in
target organs [15]. Other protease inhibitors ordinarily
present in human serum are a1-antichymotrypsin and
a2-macroglobulin [16].
Elevation of NE levels/activity has been demonstrated
in a variety of pathological conditions including cystic
fibrosis [17], acute respiratory distress syndrome,
bronchiectasis, chronic obstructive pulmonary disease
[18], type2 diabetes mellitus, atherosclerosis [19], aortic
stiffness and systolic hypertension [20]. Such changes
have been explained by a possible protease/anti-protease
imbalance. This imbalance might be due to an increased
elastase load following neutrophil influx, a reduction in
the levels or activity of the circulating inhibitors of
this enzyme, or increased non-apoptotic neutrophil
death [21].
It is unknown whether obese individuals with prehy-
pertension also have elevated NE, and if so, whether it
has a deleterious effect on pulmonary function. The aim
of the present study was to investigate the level of
serum elastase in obese prehypertensive women and to
investigate correlations with pulmonary function tests.
Methods
Ninety females were enrolled in the study, divided into
three groups (Table 1). Group 1 included 30 obese
prehypertensive women. Group 2 included 30 obese
normotensive women. Group 3 included 30 non-obese,
age-matched normotensive women (control group). The
mean ages were 33.5 ± 7.7, 34.4 ± 9 and 36.5 ± 5.2,
respectively. The obese patients were attending obesity
clinics at the Specialized Medic a lH o s p i t a l .A l lp a t i e n t s
signed an informed consent to be included in our study.
The study was approved by the local ethical committee
of Mansoura University Hospital, Internal Medicine
Department.
Blood pressure was categorized according to the JNC-
7 (1). Normal blood pressure was defined as not being
on antihypertensive medication and having systolic
blood pressure less than 120 mm Hg and diastolic blood
pressure less than 80 mm Hg. Prehypertension was
defined as not being on antihypertensive medication and
h a v i n gas y s t o l i cb l o o dp r essure of 120-139 mm Hg
or diastolic blood pressure of 80-89 mm Hg on three
occasions. Blood pressure was taken in the sitting
position after 10 min rest using a random-zero
sphygmomanometer.
All participants were subjected to thorough medical
history and clinical examination, and anthropometric
measurements were performed as follows: height was
measured to the nearest 0.5 cm; body weight was mea-
sured to the nearest 0.1 kg; body mass index (BMI) was
calculated as weight/height
2(kg/m
2). Waist circumfer-
ence (WC) was measured at the highest point of the
iliac crest.
Assay
Serum total cholesterol (TC), triglyceride (TG), and
high density lipoprotein cholesterol (HDL-c) were
assayed by commercially available kits. Low density lipo-
protein cholesterol (LDL-c) was calculated according to
Table 1 Subjects characteristics
Characteristics Group1
(n = 30)
Group2
(n = 30)
Group3
(n = 30)
Age (years) 33.5 ± 7.7 34.4 ± 9 36.5 ± 5.2
BMI (kg/m
2) 43.4 ± 9.4* 38.9 ± 4.3¤¶ 22.8 ± 1.83
WC (cm) 115.1 ± 15.4* 103.8 .6.6¶ 72.6 ± 4.6
SBP (mm Hg) 129.5 ± 5.5* 118 ± 4¶ 118.7 ± 6.3
DBP (mm Hg) 83.1 ± 2.5* 78 ± 4¶ 76 ± 4.98
FH of HTN 80% 50%¤¶ 23.3%
hs-CRP (μg/ml) 3.1 ± 0.6* 2. 3 ± 1¤¶ 1.8 ± 0.6
TC (mg %) 220.9 ± 38.2* 180.2 ± 20.6¤¶ 157.6 ± 19.04
TG (mg %) 206.4 ± 16.4* 133.7 ± 31.6¤ 95.8 ± 31.07
LDL-c (mg %) 142.9 ± 26.2* 117.7 ± 20.2¤¶ 95.5 ± 19.8
HDL-c (mg %) 37.8 ± 5.3* 42.8 ± 6.5¤¶ 52.9 ± 2.1
Data are expressed as mean ± standard deviation.
*p ≤ 0.05: group 1 vs. group 3; ¤p ≤ 0.05: group 2 vs. group 3; ¶p ≤ 0.05:
group 1 vs. group 2.
Group 1: obese prehypertensive women.
Group 2: obese normotensive women.
Group 3: normal controls.
BMI: Body mass index.
WC: Waist circumference.
SBP: Systolic blood pressure.
DBP: Diastolic blood pressure.
FH of HTN: Family history of hypertension.
hs-CRP: High sensitivity C-reactive protein.
TC: Total cholesterol.
TG: Triglyceride.
LDL-c: Low density lipoprotein cholesterol.
HDL-c: High density lipoprotein cholesterol.
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ELISA, supplied by Immunodiagnostic AG Stubenwald-
Allee 8 Ad-64625 Bensheims, according to Oremek
etal. [23]. High sensitivity CRP (hs-CRP) was estimated
using an immunoenzymometric assay supplied by
Monobind Inc., Lake Forest, CA 92630 USA, according
to Kimberly et al. [24].
Pulmonary Function Tests
Spirometry was performed according to the criteria of
the ATS using a computerized spirometery apparatus
(Jager Spirometery), and the following parameters were
determined: forced vital capacity (%FVC), forced expira-
tory volume in the first second (%FEV1), and FEV1/FVC
ratio [25].
Statistics
Excel and SPSS packages version 10 (spss, inc., Chicago,
IL, USA) were used for the statistical analysis of data.
The data were expressed as mean (±) SD for continuous
data and frequency and proportion for categorical data.
For continuous data, Student’s t-test was used to com-
pare two groups. A chi square test was used to compare
categorical data. Correlation coefficients were calculated
to evaluate associations between variables. P value =
0.05 was considered as significant at a 95% confidence
interval.
Results
Baseline characteristics of the three groups are given in
Table 1. Obese prehypertensive women (group 1) had
significantly higher BMI, WC, systolic and diastolic
blood pressure, hs-CRP, TC, TG and LDL than groups
2 and 3. HDL-c was significantly lower in group 1 than
groups 2 and 3. Obese normotensive women had signifi-
c a n t l yh i g h e rB M I ,W C ,h s - C R P ,T C ,T Ga n dL D L - c
than normal controls. HDL-c was significantly lower in
group 2 than group 3. Eighty percent of obese prehyper-
tensive women had positive family histories of hyperten-
sion, 50% in group 2 and 23% in group 3.
Serum elastase levels were significantly higher in
group 1 (405.8 ± 111.6 ng/ml) than groups 2 (336.5 ±
81.5 ng/ml) and 3 (243.9 ± 23.9 ng/ml), p = 0.008 and
p < 0.001 respectively. They were also higher in group 2
than group 3 (p = 0.001) (Figure1).
FEV1 and FVC were significantly lower in group 1
(84.6 ± 6; 75.6 ± .4.1) and group 2 (86.6 ± 6.9; 76.2 ±
6.5) than group 3 (91 ± 3.4, 93.4 ± 3.6) but there was
no statistically significant difference between groups 1
and 2 (p = 0.08, p = 0.7, respectively). The FEV1/FVC
ratio was significantly lower in group 1 (77.7 ± 8.6) and
group 2 (79.4 ± 11) than group 3 (87.8 ± 2.7) but this
reduction did not reach the obstructive limit (< 70%).
There was no significant difference in FEV1/FVC
between groups 1 and 2, p = 0.51 (Table 2).
The correlations between serum elastase level and
other parameters in group 1 are shown in Table 3. The
serum elastase levels were positively correlated with
BMI, WC, SBP, DBP, TC, TG (r = 0.62, p = 0.009),
LDL-c and hs-CRP (r = 0.7, p < 0.001), and negatively
correlated with HDL, FEV1, FVC and FEV1/FVC.
Discussion
There are clear epidemiological links between obesity
and hypertension; obesity is probably the most impor-
tant modifiable risk factor contributing to hypertension
[26]. Weight gain after age 20 substantially increases the
risk for prehypertension in non-hypertensive individuals,
while weight loss significantly lowers the risk [27]. With
respect to specific risk factors, the risk ratio for obesity
is greater in prehypertensive than normotensive subjects
[28,29]. Interestingly, a recent large-scale population-
based study demonstrated that abdominal obesity was
the strongest independent predictor of lung function
impairment [30].
The current study examined, for the first time, the
relationship between serum elastase and prehyperten-
sion in obese women and correlated its level with pul-
monary function tests. The main finding was that the
serum elastase level was significantly higher in obese
prehypertensive women than obese normotensive
women and normal controls.
These results parallel those of Niccoloff and Christova
[31], who found significant elevation of elastin-derived
protein (EDP) in obese hypertensive children with a
family history of arterial hypertension, and the level was
significantly higher than in obese non-hypertensive
children with a family history of hypertension, obese
non-hypertensive children without family history of
hypertension, and healthy non-obese children. Obese
non-hypertensive children with a family history of
hypertension had significantly higher EDP than controls,
whereas obese non-hypertensive children with no family
history of arterial hypertension did not differ from con-
trols. Also, using microangiopathy, Nicooloff et al. [32]
found significantly higher concentrations of elastin pep-
tides in obese hypertensive children and diabetic chil-
dren than in controls. Piwowar et al. [33] demonstrated
significantly higher plasma elastase in obese diabetic
patients than in lean ones. In contrast, Adeyemi et al.
[34] found that the plasma elastase levels (determined
by ELISA) in obese individuals did not differ signifi-
cantly from those in lean healthy controls.
Experimental models of hypertension in animals sug-
gest that enhanced mechanical stress induced by acutely
raising blood pressure increases the synthesis of elastin
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synthesis of matrix metalloprotinase-9 [35]. Arterial
hypertension is connected with the loss of elasticity,
increasing rigidity of the arterial wall and an abnormal
increase in collagen/elastin degradation in obese patients
with arterial hypertension [31].
A major mechanism responsible for obesity-associated
hypertension is inflammation; this increases insulin
resistance, which in turn leads to obesity while perpetu-
ating diabetes, high BP, and dyslipidemia [36]. Abnorm-
alities in circulating markers of inflammation, such as
CRPs, interleukin-6 and TNF-a a r em o r ec o m m o ni n
prehypertension than normotension [37,38]. Mania et al.
[39] speculated that elastase may be used as a non-
specific indicator to screen inflammation and infection.
Cardiovascular complications of obesity are associated
with elevated degradation of elastic tissue [40]. It can be
inferred that proteolytic enzymes are actively involved in
the remodeling of vessel walls, causing stiffness in them
and contributing to the development of hypertension [41].
336.5
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Figure 1 Serum elastase in the studied groups. **p < 0.01 ***p < 0.001 GP1: obese prehypertensive women GP2: obese normotensive
women.
Table 2 Pulmonary function in the three groups
Pulmonary function test Group 1 Group 2 Group 3
FEV1 84.6 ± 6* 86.6 ± 6.9¤ 91 ± 3.4
FVC 75.6 ± .4.1* 76.2 ± 6.5¤ 93.4 ± 3.6
FEV1/FVC 77.7 ± 8.6* 79.4 ± 11¤ 87.8 ± 2.7
Data are expressed as mean ± standard deviation.
*p≤ 0.05: group 1 vs. group 3; ¤ p ≤ 0.05: group 2 vs. group 3.
Group 1: obese prehypertensive women.
Group 2: obese normotensive women.
Group 3: normal controls.
FEV1%: Forced expiratory volume in one second.
FVC%: Forced vital capacity.
Table 3 Correlation between serum elastase and clinical
and metabolic parameters in obese prehypertensive
women
Characteristics R P-value
BMI (kg/m
2) 0.37 0.05*
WC (cm) 0.53 0.01**
SBP (mm Hg) 0.4 0.02*
DBP (mm Hg) 0.48 0.01**
TC (mg %) 0.49 0.03*
TG (mg %) 0.62 0.009**
LDL-c (mg %) 0.45 0.02*
HDL (mg %) - 0.51 0.03*
hs-CRP (μg/ml) 0.7 < 0.001***
FEV1% - 0.28 0.13
FVC % - 0.17 0.37
FEV1/FVC - 0.28 0.32
*p ≤ 0.05 **p ≤ 0.01 ***p ≤ 0.001.
BMI: Body mass index.
WC: Waist circumference.
SBP: Systolic blood pressure.
DBP: Diastolic blood pressure.
TC: Total cholesterol.
TG: Triglyceride.
LDL-c: Low density lipoprotein cholesterol.
HDL-c: High density lipoprotein cholesterol.
hs-CRP: High sensitivity C-reactive protein.
FEV1%: Forced expiratory volume in one second.
FVC %: Forced vital capacity.
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of elastin fragments, designated ‘elastokines’ in keeping
with their cytokine-like properties. Generation of elasto-
kines from one of the longest-lived proteins in humans
might represent a strong tissue repair signal. Indeed, they
exhibit potent chemotactic activity for leukocytes, stimu-
late fibroblast and smooth muscle cell proliferation, and
display as potent a proangiogenic activity as vascular
endothelial growth factor. These elastin fragments can
also polarize lymphocytes towards a Th-1 response or
induce an osteogenic response in smooth muscle cells,
and arterial wall calcification [42].
In the present study, FEV1 and FVC were significantly
lower in both obese prehypertensive and obese normo-
tensive women than in normal controls, but there was
no statistically significant difference between the prehy-
pertensive obese patients and normotensive obese sub-
jects. These results are consistent with those of Lazarus
et al. [43] who reported that increasing BMI is typically
associated with reduction in FEV1 and FVC. Also, Bach
et al. [44] observed that obesity in dogs caused airflow
limitation during the expiratory phase.
The FEV1/FVC ratio was lower in both obese prehy-
pertensive and obese normotensive women than in lean
normotensive women but did not reach the obstructive
limit (below 70%). Sin et al. [45] reported that an FEV1/
FVC ratio below 70% (the spirometric signature of air-
flow obstruction) is not a feature of respiratory disease
associated with obesity.
Suzuki et al. [46] suggested that neutrophil elastase
contributes to the induction of airway constriction and
airway responsiveness in various inflammatory lung dis-
eases with pulmonary neutrophil infiltration, such as
chronic obstructive pulmonary disease and possibly
bronchial asthma. Nevertheless, the elastase-anti-elastase
hypothesis, while popular for a time, is no longer con-
sidered the sole explanation for the pathogenesis of
emphysema, in the same way that neutrophils are no
longer believed to represent the only cellular source of
elastolytic enzymes in the lung [47]. Other factors have
also been implicated in air space enlargement, including
other classes of proteinases (matrix metalloproteinases
and cysteine proteinases), oxidative stress, and apoptosis
of lung structural cells [48].
TC, TG, and LDL-c were significantly higher in obese
prehypertensive women than obese normotensive sub-
jects and healthy controls. This is in agreement with
Ganguly et al. [49] who concluded that the prehyperten-
sives had higher levels of TC, TG, and LDL-c than nor-
motensives in a cross-sectional community-based study
including 327 prediabetic Omani adults. Similar findings
were reported by Liszka et al. [4] and Grotto et al. [50].
Our results showed significantly greater hs-CRP in
obese prehypertensive women than obese normotensive
women and healthy controls. These results are consis-
tent with those from a study by King et al. [38], who
demonstrated significantly higher CRP in prehyperten-
sion than normotension.
In addition, we found significant correlations between
serum neutrophil elastase and BMI, WC, SBP, DBP,
lipid profile and hs-CRP in obese prehypertensive
women. These data suggest an association between elas-
tin turnover activity and vascular complications of obe-
sity and hypertension.
One large study of 1,400 patients with cardiovascular
disease demonstrated that the serum elastase activity
(SEA) was directly proportional to BMI and glucose
level and inversely proportional to the triglyceride level.
The authors concluded that the remodeling of vessel
walls depends not only on the degradation of elastin but
also on lipid metabolism [51]. Similarly, SEA was stu-
died as part of an epidemiological study of vascular and
cognitive aging (EVA study). SEA was positively and sig-
nificantly correlated with BMI, systolic blood pressure
and triglycerides in both sexes. In multivariate analysis,
independent determinants of an increased SEA were
age, triglycerides and glucose in men and TGs in
women [52]. Paczek et al. [41] also found positive direct
correlations between BMI, systolic and diastolic blood
pressure and elastase activity.
We observed a significant negative correlation
between serum elastase and HDL-c. Our results agree
with those of Landi et al. [53], who found significant
negative correlations between HDL and HDL2-c and
elastase inhibitory capacity in both male atherosclerosis
patients and control subjects. Also, elastase-type activity
and elastase inhibitory capacity were determined in the
sera of atherosclerotic patients, those suffering from
ischemic vascular disease located at various sites, and
control subjects. There was a significant negative corre-
lation between the inhibitory capacity and HDL-c [54].
Polacek et al. [55] confirmed that both LDL and HDL,
two of the major plasma lipoprotein classes, can affect
the export from PMN of an elastase that exhibits pro-
teolytic action on apo-B and apo-A-11 in vitro.
Our results showed a significant positive correlation
between neutrophil elastase and hs-CRP in obese prehy-
pertensive women. Consistent with these findings,
Zureik et al. [56] reported that serum elastase activity
was associated with fibrinogen and CRP after a 4 year
follow-up in a population of 859 subjects between
59 and 71 years of age. Kakuta et al. [57] suggested that
CRP degradation products generated by neutrophil elas-
tase promote neutrophil apoptosis. Cleavage of CRP by
neutrophil elastase may offer protection from inflamma-
tory injury.
There was an insignificant negative correlation
between the increased level of serum neutrophil elastase
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women, in agreement with Bizeto et al. [58], who found
negative correlations between increased neutrophil elas-
tase level and impairment of FVC, FEV1 and the FEV1/
FVC ratio in patients with chronic obstructive pulmon-
ary disease.
From the previous discussion, it seems that elevated
serum elastase in obese women could reflect a minor
inflammatory state and might be considered an impor-
tant contributor to the development of prehypertension
and possible lung function impairment. Also, the eleva-
tion of serum elastase in obesity may explain its associa-
tion with both hypertension and air flow limitation;
additional studies are needed to elucidate the signifi-
cance of this observation.
Conclusion
Serum neutrophil elastase concentration is elevated in
obese prehypertensive women and its level is correlated
with inflammatory markers (high sensitivity C-reactive
protein), dyslipidemia and air flow dysfunction.
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